<DOC>
	<DOCNO>NCT01787396</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety initial combination therapy Gemigliptin 50mg q.d Metformin q.d compare either monotherapy treatment na√Øve patient type 2 diabetes , In word , proof superiority initial combination therapy Gemigliptin Metformin monotherapy .</brief_summary>
	<brief_title>Phase III Trial Evaluate Efficacy Safety Initial Combination Therapy With Gemigliptin 50mg q.d Metformin q.d</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients type 2 diabetes mellitus 2 . Adults 20 age 3 . Patients hemoglobin A1c ( HbA1c ) 7.5 % Visit1 ( screen ) previous antidiabetic drug Visit 1 ( screen ) patient hemoglobin A1c ( HbA1c ) 7 % ~10.5 % , Patients treat metformin monotherapy Visit 1 ( screen ) . Patients previous antidiabetic drug 4 . Patients hemoglobin A1c ( HbA1c ) 7.5 % ~11 % Visit 2 ( randomization ) 1 . Patients type 1 diabetes mellitus Diabetic ketoacidosis Hyperosmolar nonketotic coma . 2 . Patients gestational diabetes , secondary diabetes 3 . Patients New York Heart Association ( NYHA ) class IIIIV congestive heart failure patient arrhythmia require treatment 4 . Patients dysfunctional thyroid gland ( abnormal level TSH ) 5 . Patients active bladder cancer . 6 . Tests need give radiation iodide dye intravenous . ( ex , intravenous urography , intravenous cholangiography , angiography , CT dye ) 7 . Severe infection , pre post operation . ( Simple surgery restriction food fluid ) , severe trauma patient . 8 . Patients pituitary insufficiency adrenal dysfunction . 9 . Patients pulmonary infarction , severe pulmonary dysfunction , hypoxemia . 10 . Patients gastrointestinal disorder ( ex . Dehydration , Diarrhea , Vomiting ) 11 . Female patient gravida lactiferous phase confirm pregnancy serum urine . 12 . Patients body mass index ( BMI ) 20 kg/m2 exceed 40 kg/m2 13 . Male patient Serum Creatinine level 1.5mg/dl , Female patient serum creatinine 1.4mg/dl . 14 . Patients alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , exceed 2.5 time bilirubin exceed 1.5 time upper limit normal range 15 . Patients take needed take drug may affect control blood glucose significantly ( ex . glucocorticoid ) 16 . Patients take thyroid hormone , warfarin , dicoumarin digoxin . 17 . Patients take CYP3A4 inducer . ( ex , Rifampicin ( Rifampin ) , Dexamethasone , Phenytoin , Carbamazepine , Rifabutin , Phenobarbital ) 18 . Patients take Furocemide , Nifedipine , Cimetidine 19 . Patients treated Antiobesity drug last 12 week prior Visit 1 ( screen ) 20 . Patients treat insulin glucagonlike peptide1 ( GLP1 ) analogue last 6 month prior Visit 1 . 21 . Patients experience myocardial infarction , unstable angina prior history coronary artery bypass surgery within 6 month prior Visit1 ( screen ) , patient arrhythmia require treatment 22 . Patients history addiction alcohol drug within 1year prior Visit 1 ( screen ) . 23 . Patients history Diabetic ketoacidosis Hyperosmolar nonketotic coma . 24 . Patients history hypersensitivity gemiglpitin Dipeptidylpeptidase4 ( DPP4 ) inhibitor . 25 . Patients history hypersensitivity metformin biguanides . 26 . Patients history hypersensitivity Pioglitazone HCl Thiazolidinediones 27 . Patients participate clinical trial within 3 month prior Visit1 ( screen ) . 28 . Patients reason investigator decide eligible study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>